Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PURPOSE: Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component. METHODS: Safety and efficacy of polatuzumab vedot...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehn, Laurie H., Herrera, Alex F., Flowers, Christopher R., Kamdar, Manali K., McMillan, Andrew, Hertzberg, Mark, Assouline, Sarit, Kim, Tae Min, Kim, Won Seog, Ozcan, Muhit, Hirata, Jamie, Penuel, Elicia, Paulson, Joseph N., Cheng, Ji, Ku, Grace, Matasar, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032881/
https://www.ncbi.nlm.nih.gov/pubmed/31693429
http://dx.doi.org/10.1200/JCO.19.00172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032881/
https://www.ncbi.nlm.nih.gov/pubmed/31693429
http://dx.doi.org/10.1200/JCO.19.00172

Ejemplares similares